DARA BioSciences to Present Positive Results of DB959 Phase I Study at the Upcoming 71st ADA Scientific Sessions

DARA BioSciences, Inc. DARA announced that an abstract has been accepted for presentation at the annual American Diabetes Association Scientific Sessions to be held in San Diego, CA, June 24 - 28, 2011. The presentation will provide details on the company's lead once-a-day, oral diabetes drug candidate DB959. The abstract entitled "DB959-101: A Phase 1 Randomized, Placebo-Controlled, Double-Blind, Escalating Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effect of DB959Na in Healthy Male and Female Volunteers," has been selected for presentation in the session on Clinical Therapeutics/New Technology – Pharmacologic Treatment of Diabetes or its Complications. Mary Kay Delmedico, Ph.D., Director of Drug Development/Portfolio Management at DARA said, "We are looking forward to presenting these encouraging results at the ADA meeting and the continued development of DB959."